<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994890</url>
  </required_header>
  <id_info>
    <org_study_id>A4091043</org_study_id>
    <nct_id>NCT00994890</nct_id>
  </id_info>
  <brief_title>A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Long Term Study Of The Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety of three fixed dose levels of tanezumab (2.5 mg, 5 mg,
      and 10 mg) administered at an 8-week interval by subcutaneous injection multiple (7) times
      during the study treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety study of tanezumab in relief of osteoarthritis pain This study was terminated on 6
      December 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies
      which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline to Week 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory testing</measure>
    <time_frame>Day 1, Weeks 8, 16, 24, 40, 56 and 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms (ECGs)</measure>
    <time_frame>Baseline, Weeks 2, 8, 24 and 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurologic examinations, Vital Signs and Injection Site Assessments</measure>
    <time_frame>Baseline, Weeks 2, 4 ,8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-drug antibody concentrations</measure>
    <time_frame>Baseline, Weeks 8, 24, 40, 56 and 64</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Physical Function</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Stiffness</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Osteoarthritis</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI Responder Index</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response: Reduction in WOMAC Pain</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Distribution of Percent Change in WOMAC Pain</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response in Patient Global Assessment of Osteoarthritis</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Average Score</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Item: Pain When Walking on Flat Surface</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Pain Item: Pain When Going up or Down Stairs</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation Due to Lack of Efficacy</measure>
    <time_frame>Baseline to Week 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients who use concomitant analgesics for osteoarthritis</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days per week of use of concomitant analgesic medication for osteoarthritis</measure>
    <time_frame>Baseline , Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56 and 64</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">679</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>Tanezumab 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tanezumab 2.5 mg</intervention_name>
    <description>Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year</description>
    <arm_group_label>Tanezumab 2.5 mg</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tanezumab 5 mg</intervention_name>
    <description>Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year</description>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tanezumab 10 mg</intervention_name>
    <description>Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year</description>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthritis of the knee or hip based on American College of Rheumatology criteria
             with a radiographic (X ray) confirmation (a Kellgren Lawrence x-ray grade of â‰¥2);

        Exclusion Criteria:

          -  Body mass index (BMI) of &gt;39 kg/m2;

          -  Pregnancy or intent to become pregnant

          -  Planned surgical procedure during the duration of the study

          -  History of clinically significant cardiovascular, central nervous system or
             psychiatric disease

          -  Previous exposure to exogenous NGF or to an anti NGF antibody;

          -  Use of biologics other than study medication, Live or live-attenuated intranasal
             vaccines (eg, Flumist), are allowable exceptions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091043&amp;StudyName=A%20Long%20Term%20Study%20of%20the%20Safety%20of%20Tanezumab%20When%20Administered%20By%20Subcutaneous%20Injections</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <disposition_first_submitted>October 1, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 1, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2012</disposition_first_posted>
  <last_update_submitted>October 1, 2012</last_update_submitted>
  <last_update_submitted_qc>October 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double-blind safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

